Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis.

[1]  C. Di Mario,et al.  Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. , 2021, Mayo Clinic proceedings.

[2]  C. Di Mario,et al.  Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. , 2021, International journal of cardiology.

[3]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[4]  P. Lindqvist,et al.  Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic , 2020, ESC heart failure.

[5]  D. Burkhoff,et al.  Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis due to Val122Ile Mutation: Insights from Non-Invasive Pressure-Volume Analysis. , 2020, Journal of cardiac failure.

[6]  P. Michałek,et al.  Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis , 2020, Cardiology journal.

[7]  A. Dispenzieri,et al.  Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. , 2020, JAMA.

[8]  H. Vase,et al.  Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. , 2020, International journal of cardiology.

[9]  A. Petrie,et al.  Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. , 2020, European heart journal.

[10]  K. Sliwa,et al.  Sex differences in heart failure. , 2019, European heart journal.

[11]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[12]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[13]  C. Rapezzi,et al.  Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2019, European heart journal.

[14]  Eric J Velazquez,et al.  Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. , 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[16]  F. Salvi,et al.  Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure , 2018, European journal of heart failure.

[17]  A. Voss,et al.  Predictors of survival stratification in patients with wild-type cardiac amyloidosis , 2018, Clinical Research in Cardiology.

[18]  E. González-López,et al.  Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. , 2017, Revista espanola de cardiologia.

[19]  K. Shah,et al.  Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.

[20]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[21]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[22]  S. Frusconi,et al.  The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience , 2016, Journal of cardiovascular medicine.

[23]  K. Schenck-Gustafsson,et al.  Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. , 2016, European heart journal.

[24]  P. Westermark,et al.  Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition , 2015, PloS one.

[25]  Thomas P. Larsson,et al.  Individual reference values for 2D echocardiographic measurements. The Stockholm – Umeå Study , 2015, Clinical physiology and functional imaging.

[26]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  Helmut Baumgartner,et al.  Size Matters! Impact of Age, Sex, Height, and Weight on the Normal Heart Size , 2013, Circulation. Cardiovascular imaging.

[28]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Berk,et al.  Transthyretin (TTR) Cardiac Amyloidosis , 2012, Circulation.

[30]  K. Tanabe,et al.  Novel method for quantitative evaluation of cardiac amyloidosis using 201TlCl and 99mTc-PYP SPECT , 2012, Annals of Nuclear Medicine.

[31]  E. Barrett-Connor,et al.  Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. , 2011, Circulation.

[32]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[33]  S. Jensen,et al.  Heart complications in familial transthyretin amyloidosis: impact of age and gender , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[34]  G. Sobue,et al.  Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy , 2009, Journal of the Neurological Sciences.

[35]  R. Falk,et al.  Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. , 2009, American heart journal.

[36]  M. Saraiva,et al.  Transthyretin is up-regulated by sex hormones in mice liver , 2008, Molecular and Cellular Biochemistry.

[37]  A. Singleton,et al.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.

[38]  F. Salvi,et al.  Gender-related risk of myocardial involvement in systemic amyloidosis , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[39]  L. Fried,et al.  Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. , 2007, Journal of the American College of Cardiology.

[40]  B. Llamas,et al.  Hypertensive cardiac remodeling in males and females: from the bench to the bedside. , 2007, Hypertension.

[41]  R. Martins,et al.  Reproductive hormones modulate oxidative stress in Alzheimer's disease. , 2006, Antioxidants & redox signaling.

[42]  Rena Li,et al.  Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Gandy,et al.  Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain , 2000, Experimental Gerontology.

[44]  N. Wenger,et al.  Cardiovascular health and disease in women. , 1993, The New England journal of medicine.

[45]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.